Want to join the conversation?
$AMGN said it plans to submit data from Phase 3 endeavor trial for potential authorization of the Kyprolis drug in combination with dexamethasone in the EU. This data serves as basis of supplemental NDA of Kyprolis in combination with dexamethasone for patients with relapsed multiple myeloma, which has been accepted for priority review by US FDA.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.